Filing Flows

Filing Flows › Royalty Pharma (RPRX) › Next earnings date

Royalty Pharma (RPRX) earnings: beat the estimate

Royalty Pharma (RPRX) reported on Nov 4, 2026 and beat the EPS estimate: $1.21 against $1.18 (+2.4%). Revenue was $690M for Q3 2026, +13% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+2.4% vs estimate
Beat rate100%

The last report

Royalty Pharma reported revenue of $690M for the third quarter 2026 (+13% Y/Y), net earnings $145M: Income from financial royalty assets $648M, Other royalty income and revenues $42.5M. How it makes money → · Every quarter →

Royalty Pharma: EPS against the estimate, last 5 reportsRoyalty Pharma: EPS against the estimate, last 5 reportsEstimateReported$1.04$1.17Nov 25$1.33$1.47Feb 26$1.18$1.30May 26$1.27$1.32Aug 26$1.18$1.21Nov 26
Latest (Nov 26): Estimate $1.18, Reported $1.21.

Royalty Pharma's latest quarter

Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.

Questions

Did Royalty Pharma beat earnings?

Royalty Pharma (RPRX) reported on Nov 4, 2026 and beat the EPS estimate: $1.21 against $1.18 (+2.4%).

When does RPRX report earnings?

The next date is not set yet.

Does Royalty Pharma usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.